TheTechno Optimist.

RetatrutideEli Lilly—Retatrutide TRIUMPH-1: 28.3% mean weight loss at 80 weeks on 12 mg vs 2.2% on placeboRetatrutideEli Lilly—Lilly to present TRIUMPH-2 at EASD 2026: retatrutide gave large weight loss and A1C cuts in obesity with type 2 diabetesKLN-1010Eli Lilly—Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7 billion, with $3.25 billion upfront payment, closing expected H2 2026EloralintideEli Lilly—Eli Lilly advances eloralintide (amylin agonist) to phase 3 trials for obesity as monotherapy and add-on to incretin drugsOrforglipron (Foundayo)Eli Lilly—FDA approves Foundayo (orforglipron), an oral GLP-1 pill for obesity, under a national priority voucherKLN-1010Eli Lilly—Kelonia presents first-in-human Phase 1 data for KLN-1010 in vivo CAR-T at ASH 2025: 100% MRD-negative response in early cohort, no high-grade CRS or ICANSVERVE-102 (PCSK9 base editor)Eli Lilly—NEJM publishes Heart-2 Phase 1 results: VERVE-102 lowered LDL by 62% on average at the top dose, lasting at least a yearEli Lilly—Eli Lilly's market capitalization passes $1 trillionEli Lilly—Eli Lilly acquires Orna Therapeutics for up to $2.4 billion to advance in vivo CAR-T cell therapiesOrforglipron (Foundayo)Eli Lilly—Lilly to present ACHIEVE-4, its largest and longest Foundayo study in type 2 diabetes, at EASD 2026Tirzepatide (Mounjaro / Zepbound)Eli Lilly—FDA approves Mounjaro to reduce heart attack, stroke and cardiovascular death risk in adults with type 2 diabetesKLN-1010Eli Lilly—Kelonia presents Phase 1 ASCO 2026 data: durable MRD-negative responses, manageable safety in multiple myelomaRetatrutideEli Lilly—Lilly sues six companies selling unauthorised retatrutide, which is not yet approvedOrforglipron (Foundayo)Eli Lilly—UK authorises orforglipron for weight management and type 2 diabetes

KLN-1010

by Eli LillyUS

Simplify CAR-T cell therapy by making CAR-T cells inside the patient, eliminating complex manufacturing.

PilotStage 3 of 5

Phase 1 data ASH 2025, ASCO 2026 showed 100% MRD-negative response. Acquisition closing H2 2026.

Updated Jun 2026Checked 11 Oct0 updates this week

Milestones

Next · Phase 2 trial initiation
  1. Phase 1 inMMyCAR trial initiated2024Complete.
  2. ASH 2025 presentation of first-in-human Phase 1 dataDec 2025Complete.
  3. Eli Lilly and Kelonia acquisition agreement announced (up to $7B)Apr 2026Complete.
  4. ASCO 2026 presentation of Phase 1 inMMyCAR data in multiple myelomaJun 2026Complete.
  5. Acquisition closesQ3 2026Complete.
  6. Phase 2 trial initiationTarget 2027Not yet reached.

Most important updates

Upcoming

  1. 2027Phase 2 trial initiation (next)
Primer